Assessing the impact of neuropsychological disorders in multiple sclerosis patients
Impact of Neuropsychological Disorders on Visual Exploration, Walking Initiation and Walking in Multiple Sclerosis
NA · Lille Catholic University · NCT04837365
This study is testing how neuropsychological disorders affect people with multiple sclerosis to better understand their cognitive and emotional health.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | Lille Catholic University (other) |
| Locations | 3 sites (Lille and 2 other locations) |
| Trial ID | NCT04837365 on ClinicalTrials.gov |
What this trial studies
This study evaluates patients with multiple sclerosis (MS) to understand the effects of neuropsychological disorders on their condition. Participants will undergo routine neuropsychological assessments, clinical examinations, and three-dimensional gait analysis with eye tracking. The study aims to identify differences in cognitive and emotional functioning between MS patients with and without neuropsychological disorders. By analyzing these factors, the research seeks to enhance understanding of MS and improve patient care.
Who should consider this trial
Good fit: Ideal candidates are adults with relapsing-remitting multiple sclerosis who can communicate in French and meet specific health criteria.
Not a fit: Patients with significant motor or visual impairments, previous neurological conditions, or those on certain psychotropic medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better management strategies for MS patients by identifying the impact of neuropsychological disorders.
How similar studies have performed: While the specific approach of combining neuropsychological assessments with gait analysis is novel, similar studies have shown the importance of cognitive evaluations in MS management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Understanding and able to speak French * Carriers of MS with relapsing remitting form (RRMS-RR) with an EDSS \<4 * No significant motor, cerebellar or somesthesia disorders of the upper limbs or visual disturbances (side to a visual EDSS \<2) * Absence of corticosteroid intake in the last four weeks * Benefiting from health insurance coverage * Not showing any flare-ups or worsening of the disease in the last 6 weeks * No botulinum toxin injection for more than 4 months Exclusion Criteria: * People with previous neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general ailments, perceptual or dysarthric disorders preventing verbal communication or reading, * Treatment with psychotropic drugs (except benzodiazepines and hypnotics). * Refusal to participate after clear and fair information about the study. * Adults under tutorship, curatorship or safeguard of justice * With orthopedic treatment influencing walking * Pregnant woman
Where this trial is running
Lille and 2 other locations
- St Vincent hospital - neurological service — Lille, France (RECRUITING)
- St Philibert hospital - Neurologial service — Lomme, France (RECRUITING)
- St Philibert hospital - Physical Medicine and Rehabilitation — Lomme, France (RECRUITING)
Study contacts
- Study coordinator: Amélie Lansiaux, MD, PhD
- Email: lansiaux.amelie@ghicl.net
- Phone: +33 3 20 22 52 69
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis